Canadian Critical Care Translational Biology Group (CCCTBG)
Welcome to the CCCTBG
The CCCTBG was founded in 2003 to provide a forum for the development of research projects that benefit from the diverse knowledge, expertise, and advice of the CCCTBG members. The aim is to merge scientific rigour with translational research relevance.
Follow CCCTBG on X: @CCCTBG_Canada
Quick links
‣ CCCTBG Trainee Travel Award application (click to download). Please send via email to Dr. Patricia Liaw by April 26, 2024.
‣ Spring 2024 Meeting Page (intranet)
Photos: Lake Louise Inn January 2023; Hotel Nelligan Montreal May 2022
The purpose of the CCCTBG is to:
- Develop national collaborative multi-center studies in adult and pediatric critical care translational biology research
- Provide a national venue for continuing education about scientific research methodologies and their applications
- To develop research projects that benefit from the diverse knowledge, expertise, and constructive advice of members. In doing so, aiming to merge scientific rigour with translation research relevance
- To develop and execute research projects which are investigator-initiated and clearly affiliated with the CCCTBG. Ownership of the intellectual ideas will remain with the investigator who brings the idea to the table and will not be used by others or given to others for development.
- Large number of research programs (>20), discovery of novel biomarkers and therapies, and translation of discoveries to the bedside.
- Over 40 papers have been published on behalf of the CCCTBG, many of which are in collaboration with the CCCTG.
- The CCCTBG has one of the largest pan-Canadian biobanks with plasma and genomic samples from almost 1000 critically ill patients collected longitudinally.
- The biological samples are linked to electronic databases containing a comprehensive amount of clinical data.
Executive Committee
Committee Members
Grants
“Sepsis Research Network”, CIHR Network Grant, $5.7 M. Investigators: Alison Fox-Robichaud (PI) & 190 colleagues.
“Translational studies of heparin in sepsis-induced immunothrombosis”, CIHR Project Grant, $665,000 (2023-2028). Investigators: Patricia Liaw (PI), Alison Fox-Robichaud, Asher Mendelson, Manoj Lalu, Ryan Zarychanski, Patrick Lawler, Braedon McDonald.
“Intravenous DNase I for the treatment of sepsis: A Phase 1 safety and feasibility study in ICU patients”, CIHR Project Grant, $398,000 (2023-2028). Investigators: Patricia Liaw (PI), Alison Fox-Robichaud (Co-PI), Martin Sirois (Co-PI), Jan-Alexis Tremblay (Co-PI), Marcelo Zapata, Sameer Parpia, Jonathan Spicer, M. Mead
“Mechanistic studies of cell-free DNA and histones: at the interface of innate immunity, coagulation, and inflammation”, CIHR Project Grant, $546,976 (2018-2023). Investigator: Patricia Liaw (PI).
“Mechanisms by which cell-free DNA modulates coagulation & inflammation”, CIHR Project Grant, $431,968 (2014-2018). Investigator: Patricia Liaw (PI).
Team Sepsis to Dr. Alison Fox-Robichaud from Hamilton Health Sciences Strategic Initiative. Co-investigators: P.Liaw, A. Worster, C. Main, M. Surette, M. Parker, K. Choong, P. Kavsak
“Five Percent Albumin vs Normal Saline as Fluid Resuscitation Strategies for the Management of Early Suspected Septic Shock (PRECISE)” pilot trial, CBS, 2009-2010, Tinmouth, Alan T et a
“Studies of Plasma DNA in Sepsis”, CIHR, $794,086 (2010-2015) Patricia Liaw (PI), Alison Fox-Robichaud
“Fluid Resuscitation in Sepsis: Effects of Inflammation and Coagulation”, CBS, $401,063 (2010-2013) Alison Fox Robichaud (PI), Patricia Liaw
"Sepsis-Associate Encephalopathy", Physicians Services’ Incorporated Foundation, $166,000 (2011-2013) Douglas Fraser (PI), Gedas Cepinskas, Claudio Martin, Bryan Young